 |
|
Vitamin E Supplementation, Cardiovascular Events, and Cancer—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: Dr Richey raises the potential confounding effect of glitazone use on heart failure. We did not collect detailed data on glitazone use in HOPE and HOPE-TOO because the trial was designed in the early 1990s, before recognition of the potential impact of glitazones on heart failure. However, HOPE is a randomized double-blind trial, so that it is unlikely that glitazones would be preferentially used in the vitamin E group. Furthermore, we did collect data on overall use of oral hypoglycemic agents and this was similar in the vitamin E and placebo groups (22.2% vs 21.4% at baseline, 23.8% vs 21.3% at 4 years, and 24.5% vs 24.6% at study end, respectively). We have previously reported that vitamin E has a neutral effect on glycemic control and on the development of new-onset diabetes mellitus,1 which further makes a differential use of glitazones unlikely.
Dr Gaby correctly points out that . . . [Full Text of this Article]
Eva Lonn, MD, MSc
lonnem@mcmaster.ca
Population Health Research Institute
McMaster University
Hamilton, Ontario
RELATED ARTICLES
Vitamin E Supplementation, Cardiovascular Events, and Cancer
Robert M. Richey
JAMA. 2005;294(4):425.
EXTRACT
| FULL TEXT
Vitamin E Supplementation, Cardiovascular Events, and Cancer
Alan R. Gaby
JAMA. 2005;294(4):425.
EXTRACT
| FULL TEXT
Vitamin E Supplementation, Cardiovascular Events, and Cancer
Robert W. Jarski, Kenneth R. Hightower, and Michael I. Dangovian
JAMA. 2005;294(4):425-426.
EXTRACT
| FULL TEXT
Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer: A Randomized Controlled Trial
The HOPE and HOPE-TOO Trial Investigators
JAMA. 2005;293(11):1338-1347.
ABSTRACT
| FULL TEXT
|
